Navigation Links
BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
Date:8/19/2007

NOVATO, Calif., Aug. 13 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that AnGes MG, Inc. (AnGes), BioMarin's marketing and distribution partner in Japan, has submitted a Biologics License Application (BLA) for Naglazyme(R) (galsulfase) to the Japanese Ministry of Health, Labour and Welfare.

"We are pleased to be working with AnGes to bring the first drug treatment option to MPS VI patients in Japan," said Stephen Aselage, Senior Vice President of Global Commercial Development at BioMarin. "Patient advocacy groups and medical societies in Japan have shown a strong interest in Naglazyme, and we are honored to bring this life-altering therapy to MPS VI patients in the U.S., Europe, and now to other parts of the world."

BioMarin established a marketing and distribution agreement with AnGes in December 2006, through which AnGes obtained exclusive rights to market Naglazyme in the Japanese market. Naglazyme was approved by the U.S. Food and Drug Administration (FDA) in May 2005 and by the European Commission (EC) in January 2006. As the first drug approved for MPS VI, the FDA and EC have both designated Naglazyme as an orphan drug, conferring seven years of market exclusivity in the United States and 10 years of market exclusivity in the European Union. In addition, Naglazyme obtained orphan designation in June 2007 from the Ministry of Health, Labour and Welfare (MHLW) in Japan.

About MPS VI

MPS VI (also known as Maroteaux-Lamy syndrome) is a debilitating, life-threatening genetic disease caused by a deficiency of the enzyme N-acetylgalactosamine 4-sulfatase. This enzyme deficiency leads to the accumulation of certain complex carbohydrates, glycosaminoglycans (GAGs), in the lysosomes, giving rise to progressive cellular, tissue and organ system dysfunction. The majority of individuals with MPS VI die from disease-related complications between childhood and early adulthood. Additional informat
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.

Copyright©2007 PR Newswire.

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
2. GenoLogics Announces Bioinformatics Partnership with Illumina
3. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
4. AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results for Anti-Cancer Compound Perifosine at ASCO Meeting
5. AEterna Zentaris Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting
6. Inovio Biomedicals Partners to Present New Data from Two Cancer Immunotherapy Clinical Trials
7. Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Companys Investigational Drug to Treat Cocaine and Methamphetamine Addiction
8. Vical Licensee AnGes MG Announces Positive Results of Phase 3 Angiogenesis Trial in Japan
9. KineMed Presents Data Measuring Changes in Reverse Cholesterol Transport for the First Time
10. First Controlled Large-Scale Intervention Angiotensin Receptor Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study Demonstrates Significant Reduction in Blood Pressure and Protection of Organs with Valsartan
11. AEterna Zentaris Reports Positive Results with Cetrorelix in BPH for Japanese Phase 2a Trial

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...K,Md.,Nov.25/PRNewswire-USNewswire/--RemediumTechn...amthatstopsseverebleeding,wonfirstprizeand$10,000i...curityChallenge2009,companyofficialsannouncetoday....world,Remedium,steampitchedtheirinventionattheGSCS...ness. ,, Remedium( www.remediumtechnologies.com...
(Date:11/25/2009)...v.25/PRNewswire/--Reportlinker.comannouncesthatane..., MammographyEquipment-AGlobalMarketPerspectiv...mmography-Equipment---A-Global-Market-Perspective....ializedaswellasdevelopingnationsisaprincipalfactor...scalatingawarenessaboutbreastcancerhasallowedwomen...
(Date:11/25/2009)...,N.C.,Nov.25/PRNewswire/--CempraPharmaceuticalsInc...ndchiefexecutiveofficer,willpresentatthePiperJaffr...mber1,2009,atTheNewYorkPalaceHotelinNewYorkCity.Dr...adingantibioticclinicalprogramsforthetreatmentofdr...mpraPharmaceuticals ,, Foundedin2006,CempraPha...
Breaking Medicine Technology:Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 2Reportlinker Adds Mammography Equipment - A Global Market Perspective 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 4Reportlinker Adds Mammography Equipment - A Global Market Perspective 5Reportlinker Adds Mammography Equipment - A Global Market Perspective 6Reportlinker Adds Mammography Equipment - A Global Market Perspective 7Lumenis Completes 2415 Million Equity Financing From New and Existing Investors 50469 1Lumenis Completes 2415 Million Equity Financing From New and Existing Investors 50469 2Lumenis Completes 2415 Million Equity Financing From New and Existing Investors 50469 3Psoriasis Cure Now Welcomes Institute of Medicine Report Urging Comparative Effectiveness Research on Psoriasis But Worries About Risk of Rationing 50467 1Psoriasis Cure Now Welcomes Institute of Medicine Report Urging Comparative Effectiveness Research on Psoriasis But Worries About Risk of Rationing 50467 2Barriers Hinder EMS Workers From Using Best Resuscitation Practices 50465 1Barriers Hinder EMS Workers From Using Best Resuscitation Practices 50465 2Barriers Hinder EMS Workers From Using Best Resuscitation Practices 50465 3Barriers Hinder EMS Workers From Using Best Resuscitation Practices 50465 4
... Australia , May 22 The widely-used Affymetrix Wh...ay platform, normally used to assay gene expressio...ic splicing. Research published today in the open ... how to monitor alternative splicing activity on a...microarray technologies. , , Alternative splicing...
...-class treatment for inhalation anthrax - , , ROC...Nasdaq: HGSI ) today announced that it has submi...U.S. Food and Drug Administration (FDA) for its hu...mab) for the treatment of inhalation anthrax. , ...0080416/HGSLOGO ) , , The BLA submission incl...
Other Medicine Technology:Getting More From Whole-Transcript Microarrays 2Getting More From Whole-Transcript Microarrays 3Human Genome Sciences Submits Biologics License Application to FDA for ABthrax(TM) 2Human Genome Sciences Submits Biologics License Application to FDA for ABthrax(TM) 3Human Genome Sciences Submits Biologics License Application to FDA for ABthrax(TM) 4
(Date:11/25/2009)..., TORONTO,Nov.25/PRNewswire/-SentinelleMedica...cedvisualizationsoftwarelaunchesasuiteofnewleading...ngsoftwareplatformatthisyear,sRadiologicalSocietyo...ec.5,2009(Booth5800,HallA).Theapplicationsleverage...pecializedMRIimagingcoilsandsupportmultipleimaging...
(Date:11/25/2009)..., LOSANGELES,Nov.25/PRNewswire-USNewswire/--T...ctionstodetermineexecutiveleadershipfor2010. ,,...withspecialtiesinpublicpolicy,law,finance,governme...ship.TheBoardalsocomesfromawiderangeofpersonalback...omen,somelivingwithHIVthemselves,andrepresentingmu...
(Date:11/25/2009)... Long-term survivors of testicular cancer who were...e severe side effects, including neurological side...were not treated with chemotherapy, according to a...urnal of the National Cancer Institute . , Maria...ukeland University Hospital, in Bergen, Norway, an...
(Date:11/25/2009)... Does stress increase blood pressure? This simple...or many years. New Stress-related gene Modulates ...crease blood pressure? This simple question has b... Now new research has for the first time establish... blood pressure response to stress in mice as well...
(Date:11/25/2009)... Evaluation and treatment ... Woodstock (Vocus) November 25, 2009 -- ... nasal vaccines and H1N1 vaccine shots at four Cen... another shipment of vaccine has arrived. The clin...l Lake and McHenry and will be open as follows: , ...
Breaking Medicine News(10 mins):Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 3Health News:Black AIDS Institute Announces 2010 Board Election Results 2Health News:New stress-related gene modulates high blood pressure in mice and men 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 3Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 4
...ormerly of Harvard University,s Office of General ... All Legal Aspects of the Company, WALTHAM, Mass....leading research and advisory firms for pharmaceut...ny. Ms.,Silver comes to Decision Resources with an...
...URLINGTON, Mass., July 24 Palomar Medical,Technol...of laser- and,light-based devices for hair removal...terly conference call of its 2008 second quarter f...Time on,that day. The telephone replay will be ava...
... Chicago, 24 July 2008 The editors of Neurothera...uly issue, devoted to "Novel Therapeutics for Alzh...neurotherapeutics.org/ ) is the journal of the Ame...nference on Alzheimer,s Disease (ICAD), being held...
...Mark,s Breathe Easy Tour, Inspires Those with Chro...Enjoy Life, SAN DIEGO, July 24 SeQual Technologi...rk,s Breathe Easy Tour," a,SeQual-sponsored initia...h as chronic obstructive pulmonary,disease (COPD)....
...ATESVILLE, Ind., July 24 Hill-Rom Holdings,Inc.,s...release will be,issued Wednesday, August 6, 2008. ...following morning on Thursday, August 7, 2008 at 8...eased to,the public after the NYSE close on Wednes...
...EXICO CITY, July 24 New research from the Journal...issue on HIV/AIDS will be,released to the media, c...Four of the world,s top HIV/AIDS researchers will ... is embargoed until,10 a.m. (CT) Sun., Aug. 3, 200...
Other Medicine News:Health News:Lori Silver Joins Decision Resources, Inc. as General Counsel 2Health News:Palomar Medical Technologies to Host Second Quarter 2008 Financial Results Conference Call and Webcast on July 31, 2008 2Health News:Neurotherapeutics presents special issue on new treatments for Alzheimer's disease 2Health News:SeQual Technologies, American Lung Association of California and Seton Medical Center Partner to Support Survivor & Cyclist in 500-Mile California Ride 2Health News:SeQual Technologies, American Lung Association of California and Seton Medical Center Partner to Support Survivor & Cyclist in 500-Mile California Ride 3Health News:SeQual Technologies, American Lung Association of California and Seton Medical Center Partner to Support Survivor & Cyclist in 500-Mile California Ride 4Health News:Hill-Rom Holdings, Inc. Invites You to Join its Fiscal 2008 Third Quarter Earnings Webcast 2
.../Cuff is specifically designed to treat children's...ic benefits of controlled compression to minimize ...in. Due to the unique design of the cuff, it can b...of the patient. The Pediatric Ankle Cryo/Cuff is i...
...is designed to stabilize the knee in full extensio...es the knee with cushioned straps, and is shaped t...tension. Because of its stability, lightweight des... ideal for post-op stabilization.,The Knee Immobi...
Front Closure Clavicle Support
Shoulder Stabilizer
Medicine Products: